DQWS
DSwiss, Inc.0.0390
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.07MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
DSwiss revenue fell 57% y/y to $442K in Q3 ended September 30, 2025, yet YTD sales climbed 19% y/y to $2.5M, driven by healthcare products in Malaysia. Gross profit dropped to $59K from $113K y/y while margins held near 13%, but SG&A expenses eased 16% y/y to $140K, swinging to a $98K net loss from $61K prior. Cash dipped to $368K amid $19K operating outflow; finance leases total $131K at 3.7% through 2030. New office lease added $156K ROU asset. Customer concentration persists. Controls remain weak.
8-K
Director resigns; sole director remains
10-Q
Q2 FY2025 results
DSwiss revenue doubled to $1.0M in Q2 FY2025 ended June 30 (y/y +76% from $579K), pushing six-month total to $2.0M (+93% y/y), while gross profit hit $149K (+12% y/y) on steady margins. Net income of $32K topped prior-year $21K, fueled by other income and controlled SG&A, though six-month profit dipped to $171K from $199K on lease expenses. Cash swelled to $581K with $149K operating cash flow; finance leases total $95K at 3.6-3.7% through 2029. New office lease started March 2025. Customer concentration runs 60% to one buyer. Controls remain weak.
10-Q
Q1 FY2025 results
DSwiss revenue doubled to $1.0M for Q1 ended March 31, 2025 (up 112% y/y from $471K), yet gross profit slipped to $263K from $270K as cost of revenue surged. Net income fell to $139K from $178K, trimmed by higher SG&A and new lease expenses, while EPS dropped to $0.0007 across stable 207M diluted shares. Cash dipped to $305K amid $85K operating outflow (derived), with $99K finance leases (3.62-3.70% rates, maturing 2025-2029) and $159K operating leases added. All revenue flowed from Malaysia health products. Customer concentration persists.
10-K
FY2024 results
DSwiss doubled FY2024 revenue to $3.11M, up 111.8% y/y from $1.47M, driven by OEM/ODM nutraceutical and skincare sales, yet gross margin slipped to 20.0% from 24.4% as costs rose in tandem. Operating expenses climbed 64% to $604K on higher SG&A, but net income flipped to $22K profit from a $50K loss. Cash swelled to $397K with $183K from operations; vehicle loans total ~$118K. No quarterly breakdowns disclosed. Internal controls remain weak.
IPO
Website
Employees
Sector
Industry
CLX
Clorox Company (The)
99.82-1.90
DSS
DSS, Inc.
0.95-0.04
DSY
Big Tree Cloud Holdings Limited
0.30+0.00
ELF
e.l.f. Beauty, Inc.
78.77+0.17
HNST
The Honest Company, Inc.
2.86+0.05
NATR
Nature's Sunshine Products, Inc
22.38-0.85
NUS
Nu Skin Enterprises, Inc.
10.51+0.01
PHH
Park Ha Biological Technology C
0.39-0.00
PTNM
Pitanium Limited
10.39+0.00
SKIN
The Beauty Health Company
1.41+0.03